ClinConnect ClinConnect Logo
Search / Trial NCT04855396

The Biomarkers in the Hyperbaric Oxygen Brain Injury Treatment Trial (BioHOBIT)

Launched by UNIVERSITY OF MICHIGAN · Apr 18, 2021

Trial Information

Current as of July 23, 2025

Recruiting

Keywords

Monitoring Biomarkers Predictive Biomarkers Glial Fibrillary Acidic Protein Neurofilament Light Chain High Sensitivity C Reactive Protein

ClinConnect Summary

The BioHOBIT trial is researching how certain biological markers in the blood can help doctors understand and treat severe traumatic brain injuries (TBI) more effectively. Currently, there aren’t any effective treatments for severe TBI, and doctors mostly rely on physical examinations, which can be challenging because patients are often unconscious or sedated. This study aims to test specific blood markers—like GFAP, NfL, and hsCRP—to see if they can predict how well patients respond to a treatment called hyperbaric oxygen therapy (HBOT). By identifying these markers, the researchers hope to improve treatment plans and make future clinical trials more efficient.

To be eligible for this study, participants must already be enrolled in the ongoing HOBIT trial, which explores the best doses of HBOT for TBI patients. People with severe anemia or those from whom blood samples cannot be taken will not be included. If you choose to participate, you can expect to provide blood samples and contribute to important research that could one day help other patients with severe TBI. This trial is currently recruiting participants of all genders aged between 18 to 74 years old.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Enrolled in HOBIT (this is an ancillary study to the HOBIT Trial)
  • Exclusion Criteria:
  • Profoundly anemic (subjects who are profoundly anemic require blood transfusion)
  • Blood samples cannot be obtained

About University Of Michigan

The University of Michigan, a leading academic institution renowned for its commitment to advancing healthcare and medical research, serves as a prominent clinical trial sponsor. With a robust infrastructure that supports innovative research initiatives, the university leverages its multidisciplinary expertise to conduct a wide array of clinical trials aimed at improving patient outcomes and advancing medical knowledge. Through its state-of-the-art facilities and collaborative environment, the University of Michigan fosters partnerships between researchers, clinicians, and industry leaders, ensuring the development of cutting-edge therapies and interventions that address pressing health challenges.

Locations

West Palm Beach, Florida, United States

Minneapolis, Minnesota, United States

Omaha, Nebraska, United States

Baltimore, Maryland, United States

Detroit, Michigan, United States

Hamilton, Ontario, Canada

Durham, North Carolina, United States

Lexington, Kentucky, United States

Iowa City, Iowa, United States

San Diego, California, United States

Columbus, Ohio, United States

Omaha, Nebraska, United States

Patients applied

0 patients applied

Trial Officials

Frederick Korley, MD, PhD

Principal Investigator

University of Michigan

William Barsan, MD

Principal Investigator

University of Michigan

Gaylan Rockswold, MD, PhD

Principal Investigator

Hennepin Healthcare

Byron Gajewski, PhD

Principal Investigator

University of Kansas

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials